Ketamine research published in 2025 (page 32)

ASSOCIATION OF NEUROFILAMENT LIGHT CHAIN WITH THE ANTIDEPRESSANT EFFECTS OF LOW-DOSE KETAMINE INFUSION AMONG PATIENTS WITH TREATMENT-RESISTANT DEPRESSION

The International Journal of Neuropsychopharmacology February 1, 2025 Hui-Ju Wu, *Mu-Hong Chen, Wei-Chen Lin

Abstract Background The role of neurofilament light chain (NFL) in treatment-resistant depression (TRD) is unclear. Whether baseline NFL concentrations are associated with the antidepressant effects of low- dose ketamine infusion has not been determined. Methods The NFL concentrations of 71 patients with TRD and 17 healthy controls were assessed. Patients with TRD were randomly administered a...

DOI: 10.1093/ijnp/pyae059.560 Full text Ketamine Treatment-resistant depression Antidepressant Depression economics +6

Ketamine and Esketamine in Clinical Trials: FDA-Approved and Emerging Indications, Trial Trends With Putative Mechanistic Explanations.

Clinical Pharmacology & Therapeutics February 1, 2025 Ksenia A Vekhova, Eugenia D Namiot, Jörgen Jonsson et al. 43 citations

Ketamine has a long and very eventful pharmacological history. Its enantiomer, esketamine ((S)-ketamine), was approved by the US Food and Drug Administration (FDA) and EMA for patients with treatment-resistant depression (TRD) in 2019. The number of approved indications for ketamine and esketamine continues to increase, as well as the number of clinical trials. This analysis provides a...

DOI: 10.1002/cpt.3478 Full text Esketamine. Drug. Clinical trials. Research. +8

Fluoxetine and Ketamine Enhance Extinction Memory and Brain Plasticity by Triggering the p75 Neurotrophin Receptor Proteolytic Pathway.

Biological Psychiatry February 1, 2025 Cassiano Ricardo Alves Faria Diniz, Ana Paula Crestani, Plinio Cabrera Casarotto et al. 15 citations

Diverse antidepressants were recently described to bind to TrkB (tyrosine kinase B) and drive a positive allosteric modulation of endogenous BDNF (brain-derived neurotrophic factor). Although neurotrophins such as BDNF can bind to p75NTR (p75 neurotrophin receptor), their precursors are the high-affinity p75NTR ligands. While part of an unrelated receptor family capable of inducing completely...

DOI: 10.1016/j.biopsych.2024.06.021 Full text Ketamine Neuroplasticity Binding Extinction memory +12

CircKat6b Mediates the Antidepressant Effect of Esketamine by Regulating Astrocyte Function.

Molecular Neurobiology February 1, 2025 Na Hu, Yujie Zheng, Xueru Liu et al. 7 citations

The abundant expression of circular RNAs (circRNAs) in the central nervous system and their contribution to the pathogenesis of depression suggest that circRNAs are promising therapeutic targets for depression. This study explored the role and mechanism of circKat6b in esketamine's antidepressant effect. We found that intravenous administration of esketamine (5 mg/kg) treatment decreased the...

DOI: 10.1007/s12035-024-04420-0 Full text Esketamine Astrocytes Hippocampus Stat1 +5

Optimizing esketamine administration for postoperative depression: a comprehensive study on laparoscopic bariatric surgery patients.

Psychopharmacology February 1, 2025 Jiabao Dai, Yanfeng Lu, Zhiqing Zou et al. 11 citations

Previous studies have reported conflicting findings regarding the efficacy of esketamine in managing postoperative depression. While the positive effects of subanesthetic doses esketamine have been observed in treatment-resistant depression, the response to this medication in patients experiencing depression following surgery has not been consistent. Building upon the known impact of anesthesia...

DOI: 10.1007/s00213-024-06673-y Full text Spravato Laparoscopic bariatric surgery Anesthesia anaesthesia Anesthetic +5

How Do People Who Undergo Ketamine Treatment for a Psychiatric Problem Subjectively Experience This Intervention? A Meta-Synthesis of Qualitative Studies.

International Journal of Mental Health Nursing February 1, 2025 Melanie Trimmel, Antonia Renner, Alexander Kaltenboeck 4 citations

Ketamine treatment has shown promising effects for different mental disorders. Yet, little is known on how people who receive ketamine for a psychiatric problem subjectively experience undergoing this intervention. We conducted a systematic literature search to identify relevant qualitative research on the first-person experience of undergoing ketamine treatment in a psychiatric context. 24...

DOI: 10.1111/inm.13425 Full text Ketamine Psychedelic therapy First‐person perspective Lived experience +7

Effect of ketamine on task-based functional magnetic resonance imaging findings in major depressive disorder: A mini-review.

Journal of Affective Disorders February 1, 2025 Farzaneh Ramezani, Peyman Mardani, Fatemeh Nemati et al. 4 citations

Over the last two decades, ketamine has gained significant interest in psychiatry as a potential treatment for major depressive disorder (MDD), especially in individuals who are resistant to traditional therapies or are at a high risk of suicide. Task-based functional magnetic resonance imaging (fMRI) studies can provide insight into how ketamine alters brain function and contributes to its...

DOI: 10.1016/j.jad.2024.10.118 Full text Major depressive disorder Mood disorders Task-Based FMRI Ketamine therapy +4

Acute effects of esketamine on hypoxic ventilatory response, haemodynamics, and brain function in healthy volunteers.

British Journal of Anaesthesia February 1, 2025 Simone C Jansen, Monique van Velzen, Elise Sarton et al. 11 citations

The acute hypoxic ventilatory response is a critical chemoreflex originating at the carotid bodies. This study investigates the impact of low-dose i.v. esketamine on the ventilatory response to 20 min of isocapnic hypoxia to test the hypothesis that esketamine does not affect hypoxic ventilation. In this open-label study, 18 healthy subjects received a 3-h escalating i.v. infusion of...

DOI: 10.1016/j.bja.2024.08.040 Full text Esketamine Haemodynamics Hypoxic ventilatory response Anesthesia +4

Agitation: Neurobiology and current management guidelines.

The American Journal of Emergency Medicine February 1, 2025 Christopher W. T. Miller, Mario Rullo, Sarah Van Remmen et al. 4 citations

There have been important updates in the guidelines for the management of agitation in emergency room settings, including psychiatric emergency services. This manuscript provides a synthesis of current recommendations, combined with a detailed breakdown of the neurobiology of agitation, linking these neuroscientific dimensions with the pharmacological profiles of the drugs recommended by...

DOI: 10.1016/j.ajem.2024.11.068 Full text Ketamine Agitation Antipsychotic Benzodiazepines +3

Efficacy of esketamine nasal spray over quetiapine extended release over the short and long term: sensitivity analyses of ESCAPE-TRD, a randomised phase IIIb clinical trial.

The British Journal of Psychiatry February 1, 2025 Allan H. Young, Pierre-Michel Llorca, Andrea Fagiolini et al. 7 citations

In patients with treatment resistant depression (TRD), the ESCAPE-TRD study showed esketamine nasal spray was superior to quetiapine extended release. To determine the robustness of the ESCAPE-TRD results and confirm the superiority of esketamine nasal spray over quetiapine extended release. ESCAPE-TRD was a randomised, open-label, rater-blinded, active-controlled phase IIIb trial. Patients had...

DOI: 10.1192/bjp.2024.124 Full text Esketamine nasal spray Long-term treatment Quetiapine extended release Sensitivity analysis +6

Examining the impact of comorbid posttraumatic stress disorder on ketamine's real-world effectiveness in treatment-resistant depression.

European Neuropsychopharmacology February 1, 2025 Danica E. Johnson, Nelson B Rodrigues, Sydney Weisz et al.

Depression with comorbid posttraumatic stress disorder (PTSD) is associated with more severe symptoms and a reduced response to traditional treatments. Although ketamine shows promise as a rapid-acting antidepressant for treatment-resistant depression (TRD), its effectiveness in patients with comorbid PTSD remains underexplored. Therefore, we conducted a retrospective analysis of 134 patients...

DOI: 10.1016/j.euroneuro.2024.11.008 Full text Depressive disorder Post-traumatic Stress disorders Treatment-resistant +5

Ketamine treatment in youth for fast reduction of suicidality and engagement in psychotherapy: A randomized placebo-controlled trial protocol.

Contemporary Clinical Trials February 1, 2025 Noreen A Reilly-Harrington, Tatiana Falcone, David A Jobes et al.

Suicide is a leading cause of death in young persons. While ketamine has demonstrated rapid anti-suicidal effects, its safety and efficacy in youth has not been fully investigated. The Collaborative Assessment and Management of Suicidality (CAMS), a suicide-focused treatment shown to decrease suicidal ideation and symptom distress, has never been studied in combination with ketamine. This study...

DOI: 10.1016/j.cct.2024.107777 Full text Adolescents Cams Psychotherapy Young adults +5

Safety outcomes of ketamine for treatment-resistant depression in clinical settings and development of the ketamine side effect tool-revised (KSET-R).

Psychiatry Research February 1, 2025 Adam Bayes, Thanh Vinh Cao, Ana Rita Barreiros et al. 6 citations

Ketamine and its derivates (e.g. esketamine) are increasingly used in clinical settings for treatment-resistant depression (TRD). Ketamine can give rise to acute, cumulative and longer-term side effects (SEs) across a treatment course. The Ketamine Side Effect Tool (KSET) examines adverse effects though its length has affected feasibility for use in clinical settings. To estimate the frequency...

DOI: 10.1016/j.psychres.2024.116334 Full text Adverse events Side-effects Tolerability Depression therapy +4

Systemic ketamine toxicity following dermal application of a compounded pain cream.

The American Journal of Emergency Medicine February 1, 2025 Skyler Kessler, Bernard Weigel, Ross Ellison et al. 5 citations

Ketamine is an NMDA receptor antagonist commonly used as a dissociative anesthetic and analgesic. Though it is conventionally administered via the intravenous, intramuscular, or intranasal route, use as a compounded analgesic cream is becoming increasingly common. This is a case report of a 61-year-old man who was detained by the police for erratic driving. He was transported to the emergency...

DOI: 10.1016/j.ajem.2024.12.031 Full text Dermal application Pain cream Ketamine toxicity Topical drug safety +3

Lutein Exerts Antioxidant and Neuroprotective Role on Schizophrenia-Like Behaviours in Mice.

International Journal of Developmental Neuroscience February 1, 2025 Helia Aziziha, Shahin Hassanpour, Morteza Zendehdel 2 citations

Schizophrenia is an esteemed neuropsychiatric condition delineated by the manifestation which role of the N-methyl-D-aspartate receptor (NMDAR) is important. Lutein administration exhibits protective effects via NMDA receptors. Thus, the main goal of this research was to investigate how lutein can possibly act as an antioxidant and provide protection for the brain against schizophrenia-like...

DOI: 10.1002/jdn.10407 Full text Ketamine Lutein Mice Schizophrenia‐like behaviours +4

Ketamine impairs the performance of male mice in novel recognition object test and reduces the immunoreactivity of GAD67 in the hippocampus: Role of pioglitazone.

Pharmacology, Biochemistry, and Behavior February 1, 2025 Talita Rodrigues, Getulio Nicola Bressan, Patrícia Zorzi Juliani et al.

Schizophrenia is a mental disorder characterized by positive, negative, and cognitive symptoms which is treated with antipsychotics. However, these drugs present several side effects and, some schizophrenia symptoms, like cognitive, are difficult to treat. The peroxisome proliferator-activated receptors-gamma (PPAR-γ) are expressed in dopaminergic neurons of the midbrain participating in the...

DOI: 10.1016/j.pbb.2024.173950 Full text Animal behavior Monoamine oxidase Open field Social interaction +6

Characteristics of patients with major depressive disorder eligible for and prescribed esketamine, treatment outcomes and physician experiences: a physician and patient survey in the United States.

Current Medical Research and Opinion February 1, 2025 Manish K. Jha, Amanda Teeple, Jason Shepherd et al.

Esketamine is an FDA-approved treatment for treatment-resistant depression (TRD) or major depression with acute suicidal ideation or behavior (MDSI). This analysis addressed the lack of data on real-world characteristics of patients with TRD and MDSI or prescribed esketamine. Data were derived from the Adelphi Real World Depression Disease Specific Programme a cross-sectional survey of...

DOI: 10.1080/03007995.2025.2463975 Full text Treatment-resistant depression Quality of life Treatment outcome Depression treatment +3

Abdominal Pain and Dysuria Secondary to Chronic Recreational Ketamine Use: A Case Report on K-cramps.

Cureus February 1, 2025 Eric Boccio, Jason Haidar, Michael Thiefault et al.

Medical and recreational ketamine use is increasing in the United States; however, little is known regarding the side effects associated with chronic, frequent, and high-dose use. The lack of emergency physician awareness regarding ketamine-induced abdominal pain, nausea, vomiting, and dysuria, collectively and colloquially known as K-cramps, results in delayed recognition, underreporting, and...

DOI: 10.7759/cureus.78422 Full text Substance use disorder Abdominal pain Case report Dysuria +6

Investigating novel pharmacological strategies for treatment-resistant depression: focus on new mechanisms and approaches

Expert Opinion on Drug Discovery January 31, 2025 Aline Silva de Miranda, Eliana C B Toscano, Venugopal Reddy Venna et al. 2 citations

The understanding of the multiple pathophysiological mechanisms involved in TRD may add further value to the effective treatment, contributing to a more personalized approach. Esketamine was approved for the treatment of TRD and novel drugs with rapid antidepressant actions such as psilocybin and buprenorphine have also been investigated as potential therapeutic strategies. Over the past...

DOI: 10.1080/17460441.2025.2460674 Psilocybin Depressive disorder Treatment-resistant depression trd Refractory depression +7

Treatment-resistant major depression: Systematic review of comparative efficacy of electroconvulsive therapy and ketamine

Physiology International January 30, 2025 Giullia Graeff Saldanha, Leonardo Locatelli, Izidione Antônio Miozzo Junior

AbstractDepression is the leading cause of disability worldwide. Major Depressive Disorder (MDD) is a condition characterized mostly by low or depressed mood as well as difficulty experiencing emotions, whether positive or negative. Poor adherence has sparked the interest from both physicians and patients in these alternative therapeutic approaches. Ketamine and Electroconvulsive Therapy (ECT)...

DOI: 10.1556/2060.2024.00410